Back to search results

WE BEAT CHD Study: Well-Being Program for Teens with Congenital Heart Disease

This study is testing if the WE BEAT Well-Being Education Program, a 5-week online group program, can help teenagers with congenital heart disease (CHD) better manage stress. The program aims to improve their resilience (ability to bounce back from difficult times) and overall quality of life. Researchers will compare participants who receive the WE BEAT program to those who receive usual care. The study also explores how participants' feelings about their well-being connect with their health outcomes. You may be able to join if you are 12-17 years old, have moderate or severe CHD, and speak English or Spanish. The study plans to enroll 390 participants.

Study design
This is an interventional study comparing the WE BEAT program to usual care, with a planned enrollment of 390 participants.
What's involved
Participants will engage in a 5-week group-based online well-being and skill-building program if assigned to the intervention group.
Compensation
Not stated in the trial record.
Follow-up
Resilience is measured immediately after the 5-week intervention period.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07525843

A Pragmatic Clinical Trial of the WE BEAT Well-Being Education Program in Adolescent Congenital Heart Disease: WE BEAT CHD Study

Recruiting
NAAges 12–17InterventionalSupportive care
Carelon Research
~390 participants
Updated 2026-07-17 on ClinicalTrials.gov
What's tested:Telemedicine-based resiliency-building intervention

At a glance

Recruiting sites
12 of 14 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Connor-Davidson Resilience Scale (CD-RISC)
Measured over from baseline to week 5 (immediately post-intervention).

Conditions

Patient-Reported Outcome Measures (PROMs)
Pragmatic Trial
Adolescent Congenital Heart Disease
Resiliency-building Intervention
Resilience, Psychological
Telemedicine-Based Education

Explore related trials

Congenital Heart Disease

NCT07525843

Where you'd take part

This study runs at 14 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Boston Children's Hospital

    Boston, Massachusettsstudy coordinator listed

    Recruiting

  • Children's Hospital Colorado

    Aurora, Coloradostudy coordinator listed

    Recruiting

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvaniastudy coordinator listed

    Recruiting

  • Children's Hospital of Pittsburgh

    Pittsburgh, Pennsylvaniastudy coordinator listed

    Recruiting

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohiostudy coordinator listed

    Recruiting

  • Columbia University Irving Medical Center

    New York, New Yorkstudy coordinator listed

    Recruiting

  • Emory University School of Medicine

    Atlanta, Georgiastudy coordinator listed

    Recruiting

  • Icahn School of Medicine at Mount Sinai

    New York, New Yorkstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Melissa Cousino, PhD · PRINCIPAL_INVESTIGATOR · University of Michigan

Who to contact

Jessica E Teng, MPH
[email protected]
6179723047
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age 12-17 years old
CHD of moderate or severe complexity (Class II/III, 2018 AHA/ACC ACHD, Table 4)
English or Spanish language proficiency
Receives cardiology care at a PHN or PHN auxiliary site
Parent or guardian and participant willing to comply with protocol and provide written/electronic informed consent and assent

Exclusion

CHD of mild or simple complexity (Class I, 2018 AHA/ACC ACHD, Table 4)
Prior heart transplant to treat CHD
Heart disease that is not classified as structural CHD (e.g., connective tissue disease, genetic cardiomyopathy, or acquired heart disease)
Cognitive or developmental conditions that limit program participation and/or ability to complete self-reported measures as determined by a primary cardiology clinician
Suicidality, homicidality, or psychosis in the past 12 months as per medical chart review, clinician report, or eligibility screening
Medically unable to participate (e.g., intubated, unable to respond verbally, active delirium)

What this trial measures

  • Connor-Davidson Resilience Scale (CD-RISC)from baseline to week 5 (immediately post-intervention).

    Connor-Davidson Resilience Scale© (CD-RISC©) is a self-reported, unidimensional 5-point Likert scale measuring resilience. Total scores range from 0-40 with higher scores indicating greater resilience. It has been validated for use in children and adolescents across various countries.